アブストラクト
Title | 敗血症の病態生理Up to date : 炎症と免疫・免疫麻痺 |
---|---|
Subtitle | 特集 敗血症Up to date 2020 |
Authors | 渡邉栄三*1,2 |
Authors (kana) | |
Organization | *1千葉大学大学院医学研究院総合医科学講座, *2東千葉メディカルセンター救急科・集中治療部 |
Journal | ICUとCCU |
Volume | 44 |
Number | 2 |
Page | 57-64 |
Year/Month | 2020 / 2 |
Article | 報告 |
Publisher | 医学図書出版 |
Abstract | 「要約」敗血症の病態生理の解明は日々大いなる進歩を続けている. この20年来, 敗血症は全身性炎症反応症候群を来す微生物感染症とみなされてきた. そして近年, 敗血症の定義が臓器障害を来す感染症とされるようになり, 改訂された敗血症診療ガイドラインにおいても, さまざまな病態に対する治療が取り上げられている. とくに, 急性期の蘇生的治療においてターゲットとされてきた主な病態は, 敗血症侵襲直後に続発する全身性炎症反応であり, その対策に結び付くこれまでの研究の発展は顕著である. 一方, 近年ではその超急性炎症期の後も遷延する病態悪化への免疫麻痺の関与が広く認識され, その病態がpersistent inflammation, immunosuppression and catabolism syndrome(PICS)という概念として提唱されるようになった. その免疫抑制対策が次世代の敗血症治療における1つのbreakthroughとなるであろう. |
Practice | 臨床医学:一般 |
Keywords |
- 全文ダウンロード: 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 45:486-552, 2017
- 2) Stevenson EK, Rubenstein AR, Radin GT, et al: Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Crit Care Med 42:625-631, 2014
- 3) Gentile LF, Cuenca AG, Efron PA, et al: Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 72:1491-1501, 2012
- 4) Hawkins RB, Raymond SL, Stortz JA, et al: Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. Front Immunol 9:1511, 2018
- 5) Watanabe E, Thampy LK, Hotchkiss RS: Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike. Acute Med Surg 5:309-315, 2018
残りの37件を表示する
- 6) Hotchkiss RS, Moldawer LL, Opal SM, et al: Sepsis and septic shock. Nat Rev Dis Primers 2:16045, 2016
- 7) 平澤博之: 重症敗血症/敗血症性ショックの今日的病態生理と持続的血液濾過透析(CHDF)によるその制御. 日救急医会誌 22:85-116, 2011
- 8) Tang D, Kang R, Coyne CB, et al: PAMPs and DAMPs: signal Os that spur autophagy and immunity. Immunol Rev 249:158-175, 2012
- 9) Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5, 2007
- 10) Tsujimoto H, Ono S, Efron PA, et al: Role of Toll-like receptors in the development of sepsis. Shock 29:315-321, 2008
- 11) Bierhaus A, Nawroth PP: Modulation of the vascular endothelium during infection--the role of NF-kappa B activation. Contrib Microbiol 10:86-105, 2003
- 12) Abeyama K, Stern DM, Ito Y, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267-1274, 2005
- 13) Delvaeye M, Noris M, De Vriese A, et al: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361:345-357, 2009
- 14) Bajzar L, Nesheim M, Morser J, et al: Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 273:2792-2798, 1998
- 15) Tracey KJ: The inflammatory reflex. Nature 420:853-859, 2002
- 16) Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117:289-296, 2007
- 17) Ulloa L, Deitch EA: Neuroimmune perspectives in sepsis. Crit Care 13:133, 2009
- 18) Rosas-Ballina M, Tracey KJ: Cholinergic control of inflammation. J Intern Med 265:663-679, 2009
- 19) Ward PA: The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2:439-445, 2010
- 20) Stevens JH, O'Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 77:1812-1816, 1986
- 21) Garcia CC, Weston-Davies W, Russo RC, et al: Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury. PLoS One 8:e64443, 2013
- 22) Sun S, Zhao G, Liu C, et al: Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol 49:221-230, 2013
- 23) Sun S, Zhao G, Liu C, et al: Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis 60:586-595, 2015
- 24) Kato H, Nangaku M, Hataya H, et al: Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20:536-543, 2016
- 25) Vincent JL, Castro P, Hunt BJ, et al: Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies-what intensivists need to know. Crit Care 22:158, 2018
- 26) Iba T, Watanabe E, Umemura Y, et al: Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care 7:32, 2019
- 27) Omura T, Watanabe E, Otsuka Y, et al: Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine (Baltimore) 95:e4104, 2016
- 28) Xiao W, Mindrinos MN, Seok J, et al: A genomic storm in critically injured humans. J Exp Med 208:2581-2590, 2011
- 29) Rubartelli A, Lotze MT: Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28:429-436, 2007
- 30) Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al: A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 17:281-292, 2011
- 31) Drifte G, Dunn-Siegrist I, Tissieres P, et al: Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med 41:820-832, 2013
- 32) Hashiba M, Huq A, Tomino A, et al: Neutrophil extracellular traps in patients with sepsis. J Surg Res 194:248-254, 2015
- 33) Hynninen M, Pettila V, Takkunen O, et al: Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 20:1-4, 2003
- 34) 渡邉栄三,織田成人: 敗血症に対する免疫チェックポイント阻害薬. ICUとCCU 43:25-31, 2019
- 35) Hotchkiss RS, Swanson PE, Freeman BD, et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27:1230-1251, 1999
- 36) Hotchkiss RS, Tinsley KW, Swanson PE, et al: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 96:14541-14546, 1999
- 37) Drewry AM, Samra N, Skrupky LP, et al: Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 42:383-391, 2014
- 38) Coopersmith CM, Amiot DM 2nd, Stromberg PE, et al: Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from Pseudomonas aeruginosa pneumonia. Shock 19:408-414, 2003
- 39) Watanabe E, Nishida O, Kakihana Y, et al: Pharmacokinetics, Pharmacodynamics and Safety of Nivolumab in Patients With Sepsis-induced immunosuppression: A multicenter, open-label phase 1/2 study. Shock 2019 (Epub ahead of print)
- 40) Hotchkiss RS, Colston E, Yende S, et al: Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med 45:1360-1371, 2019
- 41) Minter S, Willner I, Shirai K: Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 31:e307-308, 2013
- 42) Grimaldi D, Pradier O, Hotchkiss RS, et al: Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis 17:18, 2017